We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SSi Falls 32% in Three Months: Should You Buy the Dip or Wait?
Read MoreHide Full Article
SS Innovations International, Inc. (SSII - Free Report) shares have declined 31.8% in the past three months compared with the industry’s 14.2% decline. It has also lagged the broader Zacks Business Services sector’s 1.5% rise and the S&P 500’s 3.4% increase in the same time frame. SSII faces widening losses, mounting operating expenses, cash burn, liquidity constraints, customer financing risks, geographic concentration and weaknesses in financial reporting controls.
Image Source: Zacks Investment Research
What’s Weighing on SSII’s Performance?
SSi continues to face profitability pressures despite growing revenues. Its net loss widened to $6.2 million in the first half of 2026 from $5.9 million a year earlier, while operating losses increased to $5.9 million from $5.6 million. Operating expenses rose to $18.3 million from $12.6 million, reflecting higher research, compensation and administrative costs. Continued spending could constrain profitability unless sales growth translates into stronger operating leverage.
SSII used $6.6 million in operating cash during the first half of 2026 and carried an accumulated deficit of $62 million as of June 30, 2026. Although a private placement raised $18.5 million in net proceeds, management expects existing cash and operating income to be insufficient to fund operations for the following 12 months. The company identified substantial doubt about its ability to continue as a going concern, making additional financing and cash generation critical to its plans.
Expanding its robotic surgery platform continues to require substantial investment. Research and development expenses increased to $3.4 million in the first half of 2026 from $1.5 million a year earlier. Selling, general and administrative expenses also climbed to $8.9 million from $6.6 million, while stock-based compensation reached $5.3 million. These costs support product development and expansion but could weigh on margins until system sales and recurring revenues absorb the spending.
SSII's customer financing arrangements create working-capital pressures despite growing system sales. Net accounts receivable reached $25.5 million as of June 30, 2026, including $8.5 million classified as non-current. Some customers make payments over three to five years, and collateral is generally not required. The allowance for credit losses reached $1.2 million. Delayed payments or defaults could restrict cash availability and increase financing needs as the company pursues further installations.
SSII remains heavily reliant on India, which generated 93% of total revenues in the first half of 2026 compared with 77% a year earlier. This concentration exposes growth to changes in local hospital spending and market conditions, while international expansion requires further investment. Management also reported ineffective disclosure controls as of June 30, 2026. Weaknesses in financial reporting and geographic dependence could complicate execution and diminish investor confidence if not addressed.
Stock Valuation
From a valuation perspective, SSi appears relatively expensive. It is trading at a trailing 12-month enterprise value/sales (EV/sales) multiple of 8.64X compared with the industry’s figure of 2.78X. It is lower than one of the company’s peers, ZenaTech, Inc. (ZENA - Free Report) , but higher than that of Everforth, Inc. (EFOR - Free Report) . The metrics for the companies stood at 11.95X and 0.75X, respectively.
Image Source: Zacks Investment Research
Can SSII Power Through the Challenges?
SSi benefits from growing adoption of its affordable SSi Mantra surgical robotic system and expanding global presence. First-half 2026 revenues rose to $25 million from $15.1 million a year earlier, reflecting stronger system and instrument sales. By September 2026, its installed base reached 238 systems across 12 countries, with more than 14,000 procedures completed. Advancements in pediatric surgery and telesurgery reinforce its technological capabilities. Expanding surgeon adoption and higher system utilization could drive recurring instrument and service revenues. Potential regulatory approvals in the United States and European Union offer further growth opportunities, while recent equity funding supports expansion.
Wrapping Up
SSi's growing robotic surgery adoption, expanding global footprint and technological advancements support its long-term prospects, although persistent losses, liquidity constraints, rising operating costs and geographic concentration risks remain concerns.
Also, its valuation is higher than the industry average. For long-term investors, despite a decline in share price, SSII’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.
View the Zacks #1 Rank List
Image: Bigstock
SSi Falls 32% in Three Months: Should You Buy the Dip or Wait?
SS Innovations International, Inc. (SSII - Free Report) shares have declined 31.8% in the past three months compared with the industry’s 14.2% decline. It has also lagged the broader Zacks Business Services sector’s 1.5% rise and the S&P 500’s 3.4% increase in the same time frame. SSII faces widening losses, mounting operating expenses, cash burn, liquidity constraints, customer financing risks, geographic concentration and weaknesses in financial reporting controls.
Image Source: Zacks Investment Research
What’s Weighing on SSII’s Performance?
SSi continues to face profitability pressures despite growing revenues. Its net loss widened to $6.2 million in the first half of 2026 from $5.9 million a year earlier, while operating losses increased to $5.9 million from $5.6 million. Operating expenses rose to $18.3 million from $12.6 million, reflecting higher research, compensation and administrative costs. Continued spending could constrain profitability unless sales growth translates into stronger operating leverage.
SSII used $6.6 million in operating cash during the first half of 2026 and carried an accumulated deficit of $62 million as of June 30, 2026. Although a private placement raised $18.5 million in net proceeds, management expects existing cash and operating income to be insufficient to fund operations for the following 12 months. The company identified substantial doubt about its ability to continue as a going concern, making additional financing and cash generation critical to its plans.
Expanding its robotic surgery platform continues to require substantial investment. Research and development expenses increased to $3.4 million in the first half of 2026 from $1.5 million a year earlier. Selling, general and administrative expenses also climbed to $8.9 million from $6.6 million, while stock-based compensation reached $5.3 million. These costs support product development and expansion but could weigh on margins until system sales and recurring revenues absorb the spending.
SSII's customer financing arrangements create working-capital pressures despite growing system sales. Net accounts receivable reached $25.5 million as of June 30, 2026, including $8.5 million classified as non-current. Some customers make payments over three to five years, and collateral is generally not required. The allowance for credit losses reached $1.2 million. Delayed payments or defaults could restrict cash availability and increase financing needs as the company pursues further installations.
SSII remains heavily reliant on India, which generated 93% of total revenues in the first half of 2026 compared with 77% a year earlier. This concentration exposes growth to changes in local hospital spending and market conditions, while international expansion requires further investment. Management also reported ineffective disclosure controls as of June 30, 2026. Weaknesses in financial reporting and geographic dependence could complicate execution and diminish investor confidence if not addressed.
Stock Valuation
From a valuation perspective, SSi appears relatively expensive. It is trading at a trailing 12-month enterprise value/sales (EV/sales) multiple of 8.64X compared with the industry’s figure of 2.78X. It is lower than one of the company’s peers, ZenaTech, Inc. (ZENA - Free Report) , but higher than that of Everforth, Inc. (EFOR - Free Report) . The metrics for the companies stood at 11.95X and 0.75X, respectively.
Image Source: Zacks Investment Research
Can SSII Power Through the Challenges?
SSi benefits from growing adoption of its affordable SSi Mantra surgical robotic system and expanding global presence. First-half 2026 revenues rose to $25 million from $15.1 million a year earlier, reflecting stronger system and instrument sales. By September 2026, its installed base reached 238 systems across 12 countries, with more than 14,000 procedures completed. Advancements in pediatric surgery and telesurgery reinforce its technological capabilities. Expanding surgeon adoption and higher system utilization could drive recurring instrument and service revenues. Potential regulatory approvals in the United States and European Union offer further growth opportunities, while recent equity funding supports expansion.
Wrapping Up
SSi's growing robotic surgery adoption, expanding global footprint and technological advancements support its long-term prospects, although persistent losses, liquidity constraints, rising operating costs and geographic concentration risks remain concerns.
Also, its valuation is higher than the industry average. For long-term investors, despite a decline in share price, SSII’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.